SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, CAR-T, TCR

Adaptimmune’s ADP-A2M4CD8 Has a Best Response With Ovarian Cancer Patients; Legend’s LB1901 Ph1 Trial Initiated in the US

Here is a brief preview of this blast: On Monday, September 13, Adaptimmune reported (press release / presentation) updated data from ADP-A2M4CD8’s (MAGE-A4 SPEAR-T) Ph1 SURPASS study for multiple solid tumors. Of note, Adaptimmune highlighted ADP-A2M4CD8’s safety profile and compared initial efficacy data to the company’s first-generation MAGE-A4 SPEAR-T therapy (afami-cel; formerly ADP-A2M4). On the same day, Legend announced (press release) the start of LB1901’s (CD4 CAR-T) Ph1 trial in the US for r/r peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Below, Celltelligence provides insights on which indications Adaptimmune could prioritize, while discussing Legend’s clinical development of LB1901 in the TCL setting.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.